Rare disease focus Target orphan disease programs with Sickle Cell Disease as the lead indication and leverage opportunities for orphan drug designation and accelerated regulatory pathways to position Emmaus for market access collaborations and co-development deals.

Strategic partnerships Explore co-development and distribution partnerships leveraging current relationships such as the Cedars-Sinai collaboration and the NeoImmuneTech license/distribution deal to expand US commercialization, enhance manufacturing scale, and accelerate IND/Phase 2/3 milestones.

Clinical progress Capitalize on the positive Phase 3 results of oral L-glutamine for sickle cell conditions to engage biopharma licensees, CROs, and patient advocacy groups for joint development programs, registrational studies, and payer engagement.

Funding and growth Position Emmaus as a financially credible partner with substantial funding and mid-sized revenue, appealing to investors and potential collaborators seeking biotech with ongoing clinical milestones and growing commercial potential.

Leadership signals Leverage recent board changes and strategic leadership appointments to deliver credibility in governance, attract strategic investors, and facilitate introductions to large pharma partners for co-promotion, licensing, or platform technology collaborations.